BRIEF-Halozyme Therapeutics says Eisai and Halozyme initiate Phase 1b/2 clinical trial
July 26, 2016 at 09:14 AM EDT
* Eisai and Halozyme initiate Phase 1b/2 clinical trial with first patient dosing of eribulin in combination with PEGPH20 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)